Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Fundacion Geltamo
Sponsor

Fundacion Geltamo

Spain Avenida Valdecilla Sn, 39008 Santander, Spain

About the sponsor

Clinical research in Mantle Cell Lymphoma focuses on adult patients with indolent disease and treatment-naïve presentations, with interest in immunotherapy and BTK inhibitor-based combinations. The sponsor also supports studies in clinically indolent forms where rituximab is paired with targeted agents to address frontline treatment needs.

  • Indolent Mantle Cell Lymphoma
  • Ibrutinib and rituximab
  • Pirtobrutinib and rituximab

These trials reflect a strong therapeutic interest in non-chemotherapy approaches for MCL across multicenter settings.

About Specializations

Fundacion Geltamo runs clinical trials in conditions such as Mantle cell lymphoma, B-cell lymphoma recurrent, Hodgkin's disease, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

5 clinical trials

Mantle cell lymphoma

Recruiting

Study on the Effectiveness and Safety of Pirtobrutinib and Rituximab for Untreated Adult Patients with Indolent Mantle Cell Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Fundacion Geltamo

Study on Epcoritamab for Patients with Relapsed or Refractory Large B Cell Lymphoma

Recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Fundacion Geltamo

B-cell lymphoma recurrent

Recruiting

Study on Axicabtagene Ciloleucel for Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Fundacion Geltamo

Hodgkin's disease

Not recruiting

Title: Comparing Brentuximab Vedotin plus ESHAP versus ESHAP alone in treating patients with relapsed or refractory classical Hodgkin's Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:Fundacion Geltamo

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Ibrutinib and Rituximab for Patients with Indolent Mantle Cell Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Fundacion Geltamo

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.